European Medicines Agency (EMA) grants Orphan Designation for AOC 1001
The FDA cleared Avidity to proceed with the phase-I/II Marinatm trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1)…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Orphan Designation
Prestige Biopharma drug gets positive EMA opinion on Orphan Designation to treat pancreatic cancer
PBP1510 has already received ODD status from the US FDA in June 2020